TWD
CRNX

True Wealth Design’s Crinetics Pharmaceuticals CRNX Stock Holding History

True Wealth Design’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300 Hold
8
– – ﹤0.01% 2355
2026
Q1 		$291 Hold
8
– – ﹤0.01% 2232
2025
Q4 		$373 Hold
8
– – ﹤0.01% 2048
2025
Q3 		$334 Sell
8
-5
-38% -$160 ﹤0.01% 2146
2025
Q2 		$374 Buy
13
+12
+1,200% +$371 ﹤0.01% 1856
2025
Q1 		$34 Buy
+1
New +$37 ﹤0.01% 2474

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

True Wealth Design's CRNX Position: Q2 2026 in Review

True Wealth Design held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 8 shares worth $300. The position accounts for ﹤0.01% of the portfolio, ranked #2355.

True Wealth Design first reported a position in CRNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $374 in Q2 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • True Wealth Design held 8 shares of Crinetics Pharmaceuticals worth $300 as of Q2 2026.
  • True Wealth Design left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2355 holding.
  • True Wealth Design first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • True Wealth Design's Crinetics Pharmaceuticals position peaked at $374 in Q2 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.